



Acrux Limited (ACR:ASX)

ASX Announcement



24 August 2026

Acrux appoints Chief Medical Officer

Acrux has appointed an experienced Chief Medical Officer to support bringing its first mover Female Testosterone treatment to market

Highlights

- Acrux has appointed Dr Jolanta Airey, a highly experienced medical professional, as its Chief Medical Officer.
- Dr Airey is a physician by training and biopharmaceutical executive with more than 20 years' experience in both large pharmaceutical and smaller biotech companies.
- This experience extends across the full clinical development lifecycle, from early-phase trials through to global product approvals. It includes experience as a Medical Monitor with Acrux's specific Testosterone formulation that led to the successful launch of Acrux's male Testosterone product, Axiron®.
- Dr Airey's broad therapeutic experience will ensure that the latest thinking in clinical trial design and execution is brought to Acrux's female testosterone program.
- Dr Airey will be a key member of the Acrux leadership team tasked with delivering key parts of Female Testosterone's development strategy.

Melbourne, Australia; 24 August 2026: Acrux Limited (ASX:ACR) ("Acrux" or "the Company") is pleased to announce the appointment of highly experienced medical professional Jolanta Airey MD to the role of Acrux Chief Medical Officer.

She will be a key member of the Acrux leadership team tasked with steering the Company's Female Testosterone treatment through its pending Phase III FDA trials and its subsequent penetration of addressable markets in the US, Europe, Australia and other target geographic regions.

Experience across the clinical development lifecycle

Dr Airey is a physician by training and biopharmaceutical executive with more than 20 years of international experience leading clinical development and medical strategy for innovative therapies.

This experience extends across the full clinical development lifecycle, from early-phase trials through to global product approvals, with therapeutic expertise spanning immunology, acute neurology, rheumatology, respiratory disease, dermatology, haematological malignancies, vaccines, immunology and infectious diseases. This ensures that she can bring the best and latest thinking in clinical development strategy, Phase III clinical trial design and trial execution to Acrux's programs.

Dr Airey has specific experience as a Medical Monitor for the trials that led to the successful launch of Acrux's male Testosterone product, Axiron®.

She also possesses strong leadership credentials, with a proven track record in leading multi-disciplinary, international teams.

Dr Airey has held senior roles with several major health care companies

Immediately prior to joining Acrux, Dr Airey was Chief Medical Officer for Cynata Therapeutics Ltd from 2021 to 2026. In this leadership role, she was responsible for guiding the clinical and medical strategy of that company's cell-based therapy pipeline involving extensive work in Phase III, registrational studies.

Over her time in the latter position, Dr Airey helped devise clinical strategies and lead clinical trials for Cynata Therapeutics products in Australia and overseas.

Since 2014, Dr Airey has been an Independent expert/member and Chair of multiple Data Safety Monitoring Committees and Safety Review Committees as well as providing strategic clinical development advice to small/medium sized biopharmaceutical companies.

Dr Airey's earlier work history included Director, Translational Development at CSL Limited and senior roles with Biota Pharmaceuticals, Inc and Kendle International/INC Research.

Dr Airey's qualifications and professional certifications/affiliations

Dr Airey has a medical degree from the Vilnius University in Lithuania and completed a Residency in Occupational Medicine - Diploma as an Occupational Medicine Doctor.

She is registered with the UK's General Medical Council (GMC), and the Lithuanian Ministry of Health (Registered Occupational Medicine Doctor status).

Acrux CEO John Warmbrunn said: *“I want to personally welcome Dr Airey to Acrux’s leadership team. She will be a valuable resource as the Company sets about delivering all the critical milestones in Female Testosterone’s development strategy. She will help us progress the work required to get The Phase III FDA clinical trial for Female Testosterone underway. Dr Airey will also be an important member of the Acrux team holding discussions with potential co-development partnerships for this treatment, tie ups that will de-risk Female Testosterone’s clinical trial process and expedite its launch into target markets. I look forward to working with Dr Airey to realise the value inherent in both Female Testosterone and other IP created by Acrux, including its proven MDTs Technology.”*

Incoming Acrux Chief Medical Officer Dr Jolanta Airey, said: *“I am excited to be joining the Acrux leadership team as the Company advances the development strategy for its Female Testosterone treatment, which offers real hope for women suffering from Hypoactive Sexual Desire Disorder. It will be great to be part of the team bringing to market such a unique treatment that comes with a clear-cut first mover advantage. And I also look forward to playing a role in advancing the development and market acceptance of other parts of Acrux’s IP portfolio.”*

Authorised for release by the Board of Acrux Limited.

For more information, please contact:

John Warmbrunn

CEO & Managing Director

E: john.warmbrunn@acrux.com.au

P: + 61 3 8379 0100

Joanna Johnson

CFO & Company Secretary

E: joanna.johnson@acrux.com.au

P: + 61 3 8379 0100

Media Relations

Julia Maguire

The Capital Network

E: julia@thecapitalnetwork.com.au

P: + 61 2 7257 7338

About Acrux:

Acrux Limited (ASX:ACR) is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States.

Click here to sign up to our InvestorHub and keep up to date with company news and latest developments or for further information on Acrux Limited visit www.acrux.com.au

END.